FDA unveils guidance for ‘plug and play’ gene therapies

The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same disease.

Rhyter Times aggregates short excerpts. The full story is reported by Biopharma dive.

Read the full story at Biopharma dive →